NCT07188428Completed
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Therapy: An Analysis of Medicare Fee-for-Service (FFS) Data
Source: ClinicalTrials.gov · Last updated 23 Sept 2025
Brief summary (registry, in English)
The aim of this study was to evaluate the real-world treatment patterns, healthcare resource use and costs among patients newly diagnosed with CML who were treated with tyrosine kinase inhibitors (TKIs) in first- and second-line therapy.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 2298 (actual)
- First submitted
- 16 Sept 2025
- Start date
- 27 Feb 2024
- Primary completion date
- 2 Dec 2024
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Chronic myeloid leukaemia
- NCT number
- NCT07188428
What you commit to
- Study type: Observational
- Participants enrolled: 2298
- From 27 Feb 2024 to the primary completion date, 2 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- L Cohort:
- Patients with medical services with a procedure code for imatinib any time during the observation period.
- Patients with a diagnosis for CML remission (identified by ICD-10-CM code: C92.11) or CML relapse (ICD-10-CM code: C92.12) any time in the baseline period before the 1L initiation.
- Patients with a medical claim associated with a clinical trial drug during the baseline period before the 1L initiation up to the end of the observation period.
- Patients who received chemotherapy, or a TKI of interest or had a hematopoietic stem cell transplantation (HSCT) during the baseline period before 1L initiation.
Other
- L Cohort:
- Patients with a diagnosis for CML remission (identified by ICD-10-CM code: C92.11) or CML relapse (ICD-10-CM code: C92.12) any time before the 2L initiation.
Who the study is looking for
- L Cohort:
- Patients had at least one diagnosis for CML (International Classification of Diseases, 10th Revision, Clinical Modification \[ICD-10-CM\]: C92.1x) during the observation period.
- Patients ≥18 years of age as of the first CML diagnosis.
- Patients received imatinib, dasatinib, nilotinib, or bosutinib in 1L.
- Patients initiated 1L within a maximum of 3 months following the first observed CML diagnosis.
- Patients had at least 12 months of continuous enrollment prior to the index date.
- Patients had at least 6 months of continuous enrollment post index date (including index date).
- L Cohort:
- Patients in the 1L cohort.
- Patients received imatinib, dasatinib, nilotinib, bosutinib, ponatinib or asciminib in 2L.
- Patients with at least 12 months of continuous enrollment prior to the index date.
- Patients with at least 6 months of continuous enrollment post index date (including index date).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Coordinator of this site? Confirm its status | East Hanover | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.